Report error Found 614 Enz. Inhib. hit(s) with all data for entry = 12607
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair
TargetGTPase KRas [G12C,C51S,C80L,C118S]/RAF proto-oncogene serine/threonine-protein kinase(Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Affinity DataIC50: 10nMAssay Description:The AlphaScreen technology was used to determine IC50s for compound inhibition of KRAS G12C (present as the Cys-light (C51S, C80L and C118S), truncat...More data for this Ligand-Target Pair

















































